📣 VC round data is live. Check it out!

🧬

Multiples Top 100 BioTech Index

Curated by Multiples, this index tracks the 100 largest publicly listed biotech companies globally.

Explore the Multiples Top 100 BioTech Index

100

public companies tracked

$9.4T

cumulative enterprise value

4.3x

median EV/NTM revenue multiple

7%

median NTM/LTM revenue growth

Index Performance

This chart shows the weighted market cap evolution over time for the Multiples Top 100 BioTech Index constituents, indexed to 0% at the beginning of the period.

+26.2%

Multiples Top 100 BioTech Index

Data as of 18 May 2026. Underlying financial data from FactSet and Morningstar. S&P 500 and NASDAQ data sourced from Yahoo Finance.

Key Index Metrics

This chart shows the median evolution over time of key valuation metrics for the Multiples Top 100 BioTech Index constituents.

Valuation Benchmarks

This chart shows the regression relationship between valuation metrics across companies in the Multiples Top 100 BioTech Index.

x-axis:
y-axis:

Data as of May 18, 2026. Companies with EV multiples above 50x and y-axis values above 250% are considered non-meaningful and excluded from calculation.

Company Rankings

This chart shows company rankings by selected metric within the Multiples Top 100 BioTech Index.

Metric:

Data as of May 18, 2026. Companies with EV multiples above 50x and y-axis values above 300% are considered non-meaningful and excluded from calculation.

Companies Side-by-Side

Compare key metrics between companies in the Multiples Top 100 BioTech Index.

1:
2:
3:
Metric
Samsung
Eli Lilly
Johnson & Johnson
Market Cap
$1.1T
$896B
$546B
EV/Revenue (NTM)
2.3x
10.4x
5.6x
EV/Gross Profit (NTM)
3.3x
12.5x
7.8x
EV/EBITDA (NTM)
4.0x
20.5x
14.7x
EV/FCF (NTM)
7.1x
37.7x
21.5x
Revenue Growth
52%
24%
7%
Gross Margin (NTM)
69%
83%
72%
EBITDA Margin (NTM)
57%
51%
38%
FCF Margin (NTM)
32%
28%
26%
Rule of 40
153%
80%
45%
Rule of X
298%
125%
56%

Data as of May 18, 2026.

Cumulative Metrics

This chart shows the cumulative sum of selected metrics across all companies in the Multiples Top 100 BioTech Index, over time.

Index Methodology

Similar to the NASDAQ 100 Index, the Multiples Top 100 BioTech Index employs a modified market capitalization weighting scheme.

The weight process uses company-level weights, which are derived using company market capitalization.

Company weights are evaluated based on two rules:

Rule 1

No company's weight may exceed 24%.

Rule 2

The aggregate weight of the companies whose weights exceed 4.5% may not exceed 48%.

If neither rule is 'violated', then no adjustments are made. Only in cases where either or both of the rules are 'violated', weight adjustments are made according to a two-stage adjustment process.

Rule 1 adjustment

If no company's initial weight exceeds 24% of the Index, initial weights are used as Rule 1 weights without adjustment. Otherwise, initial weights are adjusted such that no company's weight may exceed 20% of the Index.

Rule 2 adjustment

If the aggregate weight of the companies whose Rule 1 weights exceeds 4.5% and does not exceed 48%, Rule 1 weights are used as the final weights. Otherwise, Rule 1 weights are adjusted such that:

  • The aggregate weight of the companies whose Rule 1 weights exceeded 4.5% is set to 40%.
  • Companies with Rule 1 weights below 4.5% may also have their weights adjusted to keep the initial rank order of all companies.

If the two-stage rule process results in a 'violation' of the weighting rules as previously detailed, then the process is repeated until the company weights meet the rule system.

Companies Included in the Multiples Top 100 BioTech Index

This index tracks the top 100 biotech companies across biopharmaceuticals, diagnostics, genomics, life sciences, and more.

KR
13.1%
$173
+368%
$1.1T
2.3x
52%
69%
57%
32%
153%
$2M
US
10.3%
$1,005
+36%
$896B
10.4x
24%
83%
51%
28%
80%
$1M
US
6.3%
$227
+46%
$546B
5.6x
7%
72%
38%
26%
45%
$682K
US
4.3%
$210
+13%
$372B
6.3x
9%
82%
49%
37%
58%
$1M
CH
3.8%
$52
+27%
$330B
4.4x
1%
75%
41%
24%
40%
CH
3.3%
$148
+24%
$283B
5.6x
5%
80%
41%
25%
41%
$753K
GB
3.2%
$182
+26%
$282B
$623K
US
3.2%
$111
+45%
$275B
4.7x
4%
82%
38%
31%
35%
$867K
DE
2.6%
$302
+23%
$230B
2.7x
6%
39%
19%
11%
24%
$289K
DK
2.4%
$47
-32%
$208B
5.0x
-4%
81%
48%
20%
42%
$702K
US
2.0%
$326
+13%
$176B
5.8x
3%
81%
50%
27%
53%
$1M
US
1.9%
$438
+9%
$163B
4.2x
7%
42%
26%
16%
33%
$356K
US
1.9%
$130
+18%
$161B
5.6x
4%
87%
34%
15%
25%
$2M
US
1.7%
$421
-24%
$149B
11.8x
15%
68%
45%
34%
61%
$591K
US
1.7%
$84
-37%
$147B
3.3x
12%
57%
26%
17%
40%
$385K
US
1.7%
$25
+8%
$144B
3.2x
-2%
76%
39%
26%
38%
$834K
US
1.4%
$307
-20%
$118B
4.6x
9%
65%
29%
15%
37%
$449K
US
1.3%
$57
+18%
$116B
3.2x
-2%
70%
39%
28%
37%
$1M
US
1.3%
$162
-15%
$115B
4.9x
5%
60%
32%
23%
36%
$409K
US
1.3%
$437
-1%
$111B
7.8x
9%
87%
45%
41%
52%
$2M
FR
1.2%
$43
-13%
$104B
2.1x
5%
73%
30%
17%
34%
$726K
GB
1.1%
$25
+23%
$100B
2.6x
2%
75%
35%
17%
38%
$650K
US
1.1%
$76
-8%
$98B
3.1x
6%
65%
29%
17%
35%
$353K
JP
0.9%
$50
+5%
$82B
8.5x
8%
74%
54%
34%
63%
$1M
US
0.9%
$53
-50%
$78B
3.9x
8%
70%
32%
18%
40%
$340K
US
0.8%
$698
+42%
$73B
4.1x
11%
94%
35%
35%
46%
$931K
JP
0.8%
$40
+42%
$70B
3.1x
5%
59%
31%
15%
40%
$382K
DE
0.7%
$136
+2%
$59B
2.8x
2%
59%
28%
14%
27%
$392K
CN
0.6%
$8
+0%
$53B
8.4x
16%
87%
30%
24%
43%
$230K
JP
0.6%
$33
+22%
$53B
2.7x
2%
68%
26%
18%
27%
$586K
BE
0.6%
$275
+49%
$52B
5.0x
10%
75%
36%
25%
44%
$903K
US
0.6%
$812
+41%
$51B
7.2x
31%
90%
35%
24%
76%
$2M
IN
0.5%
$20
+8%
$47B
6.3x
14%
79%
30%
19%
43%
$316K
US
0.5%
$81
+4%
$47B
6.3x
11%
78%
32%
21%
43%
$379K
CH
0.5%
$199
+45%
$47B
7.3x
19%
71%
27%
16%
46%
CN
0.5%
$15
+67%
$46B
4.9x
18%
49%
46%
30%
63%
$170K
KR
0.5%
$948
-11%
$44B
11.4x
16%
55%
54%
23%
73%
$618K
DE
0.5%
$39
-28%
$43B
1.4x
5%
40%
20%
10%
23%
$368K
DE
0.5%
$44
+54%
$43B
1.4x
1%
57%
21%
1%
21%
$572K
US
0.5%
$529
+3%
$42B
8.8x
9%
63%
36%
25%
45%
$391K
CH
0.5%
$597
-18%
$42B
4.9x
9%
37%
32%
9%
41%
$459K
CA
0.5%
$361
+214%
$42B
1.9x
48%
11%
9%
2%
62%
$461K
IL
0.5%
$35
+95%
$40B
3.1x
0%
55%
31%
15%
27%
$508K
GB
0.5%
$4
-20%
$39B
3.2x
3%
66%
27%
15%
30%
$608K
US
0.4%
$287
-6%
$38B
5.8x
42%
77%
25%
27%
75%
$1M
JP
0.4%
$71
+53%
$37B
2.1x
1%
71%
21%
10%
25%
$398K
CH
0.4%
$83
+57%
$36B
3.2x
8%
50%
23%
8%
31%
$473K
AU
0.4%
$70
-60%
$34B
2.8x
2%
52%
34%
18%
35%
$536K
US
0.4%
$24
+19%
$33B
4.2x
19%
88%
18%
11%
37%
$445K
US
0.4%
$329
-6%
$32B
5.6x
52%
57%
33%
17%
136%
$401K
US
0.4%
$112
0%
$32B
4.3x
7%
54%
30%
19%
36%
$384K
CH
0.4%
$64
-25%
$31B
3.1x
6%
61%
27%
14%
32%
$401K
US
0.4%
$74
-56%
$31B
3.9x
4%
72%
44%
28%
47%
$653K
US
0.4%
$146
+270%
$31B
82.6x
868%
91%
-428%
-388%
JP
0.3%
$16
-33%
$30B
1.9x
10%
81%
20%
13%
30%
$601K
US
0.3%
$20
-26%
$29B
4.7x
8%
63%
39%
28%
48%
$486K
CN
0.3%
$24
-28%
$29B
4.8x
9%
60%
33%
29%
40%
$226K
US
0.3%
$193
+49%
$28B
3.1x
1%
78%
31%
23%
31%
$1M
US
0.3%
$169
+21%
$28B
2.4x
6%
33%
23%
13%
29%
$175K
US
0.3%
$61
-14%
$28B
1.6x
5%
40%
18%
8%
23%
$382K
KR
0.3%
$126
+19%
$28B
7.8x
21%
63%
39%
18%
67%
$977K
CN
0.3%
$4
+36%
$27B
8.8x
13%
91%
39%
34%
51%
$246K
US
0.3%
$186
+18%
$27B
8.7x
19%
65%
-5%
4%
13%
$520K
CN
0.3%
$5
+117%
$26B
5.4x
42%
69%
59%
27%
136%
$373K
JP
0.3%
$15
+63%
$26B
2.0x
4%
81%
30%
20%
37%
$883K
DE
0.3%
$45
-9%
$25B
1.2x
4%
27%
17%
7%
20%
$148K
NL
0.3%
$25
+9%
$24B
1.4x
0%
47%
17%
8%
17%
$317K
US
0.3%
$569
+78%
$24B
6.1x
7%
88%
51%
53%
$2M
US
0.3%
$62
-28%
$24B
4.2x
12%
64%
32%
21%
43%
$420K
US
0.3%
$109
+57%
$24B
10.9x
108%
82%
-18%
-12%
144%
$364K
JP
0.3%
$20
-5%
$23B
1.3x
3%
40%
16%
1%
19%
$246K
US
0.3%
$53
+61%
$23B
8.7x
7%
94%
93%
139%
$33M
US
0.3%
$90
-7%
$23B
2.3x
-16%
80%
-58%
-55%
-82%
$494K
GB
0.3%
$60
+54%
$23B
6.0x
12%
39%
24%
15%
37%
$338K
US
0.2%
$143
+73%
$22B
4.9x
5%
68%
29%
20%
34%
$431K
CN
0.2%
$10
+48%
$21B
1.5x
45%
16%
11%
5%
72%
$302K
GB
0.2%
$29
+166%
$21B
126.6x
638%
92%
-927%
-803%
-1732%
$39K
US
0.2%
$1,032
-11%
$21B
5.3x
5%
60%
32%
22%
37%
$222K
US
0.2%
$212
-13%
$21B
3.5x
7%
44%
29%
36%
$307K
US
0.2%
$187
+8%
$21B
2.2x
6%
33%
20%
11%
27%
$197K
US
0.2%
$250
+1%
$21B
1.8x
5%
29%
17%
8%
23%
$197K
QA
0.2%
$3
+4%
$20B
4.6x
-5%
37%
32%
22%
$4M
US
0.2%
$104
+84%
$20B
US
0.2%
$49
+85%
$19B
6.9x
12%
38%
-123%
-108%
-151%
$414K
US
0.2%
$125
+38%
$19B
2.7x
4%
47%
49%
27%
67%
$2M
US
0.2%
$16
+87%
$19B
2.1x
3%
49%
30%
13%
33%
$447K
US
0.2%
$95
+46%
$19B
2.6x
10%
92%
33%
30%
43%
$2M
IN
0.2%
$70
-2%
$19B
14.0x
16%
62%
34%
11%
49%
$120K
SA
0.2%
$38
+49%
$18B
4.3x
1%
40%
45%
38%
48%
$124K
CN
0.2%
$10
+32%
$18B
5.5x
39%
87%
18%
17%
55%
$340K
CN
0.2%
$4
+35%
$18B
4.0x
17%
46%
38%
13%
54%
$255K
US
0.2%
$181
-19%
$18B
5.2x
7%
47%
31%
12%
38%
$342K
CH
0.2%
$106
-21%
$17B
4.7x
6%
71%
30%
19%
35%
$286K
US
0.2%
$76
+22%
$17B
JP
0.2%
$19
+28%
$17B
3.0x
31%
83%
46%
-6%
76%
$504K
DK
0.2%
$26
+25%
$16B
4.3x
17%
93%
31%
23%
46%
$1M
US
0.2%
$84
-9%
$16B
2.7x
4%
71%
33%
16%
36%
$484K
SE
0.2%
$47
+48%
$16B
5.1x
11%
78%
38%
13%
51%
$2M
US
0.2%
$158
+29%
$16B
3.8x
23%
98%
29%
28%
57%
$1M
FR
0.2%
$193
+61%
$16B
3.0x
10%
80%
39%
25%
47%
$853K

Explore More Indexes

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial